Equities

Scilex Holding Co

SCLX:NAQ

Scilex Holding Co

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.05
  • Today's Change0.04 / 3.96%
  • Shares traded529.57k
  • 1 Year change-43.85%
  • Beta1.2008
Data delayed at least 15 minutes, as of Sep 19 2024 17:24 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for Scilex Holding Co have a median target of 5.50, with a high estimate of 7.00 and a low estimate of 4.00. The median estimate represents a 444.55% increase from the last price of 1.01.
High593.1%7.00
Med444.6%5.50
Low296.0%4.00

Earnings history & estimates in USD

On Aug 13, 2024, Scilex Holding Co reported 2nd quarter 2024 losses of -0.31 per share.
The next earnings announcement is expected on Nov 15, 2024.
Average growth rate+11.72%
Scilex Holding Co reported annual 2023 losses of -1.28 per share on Mar 12, 2024.
More ▼

Revenue history & estimates in USD

Scilex Holding Co had 2nd quarter 2024 revenues of 16.37m. This bettered the 13.17m consensus of the 3 analysts covering the company. This was 61.81% above the prior year's 2nd quarter results.
Average growth rate+21.44%
Scilex Holding Co had revenues for the full year 2023 of 46.74m. Last year the company did not report any revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.